Eli Lilly (LLY)

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Beam Therapeutics' growing pipeline could reward patient investors.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

It is definitely a strong contender.

Maybe you should, too.

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?

Viking's latest program seeks to push the envelope in weight loss efficacy.

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Novo Nordisk is finally getting one up on its biggest rival.

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.

The psychedelic drugmaker is being acquired.

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Investors need to ask tough questions before initiating a position in this biotech company.

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.